Published on 05.08.2022
Estimated reading time: less than 1 minute
Share this article on:
Health ” The Federal Office of Public Health (OFSP) is currently examining the possibility of centralizing the purchase of a vaccine once morest monkeypox. Such a measure, however, presupposes that Swissmedic has given the green light to use the product. However, the institute has not received a request for authorization.
Whether the monkeypox vaccine will undergo a rolling review process will depend on the epidemiological situation, the therapeutic products institute said. This rolling data review is currently only planned for the Covid-19 vaccine.
The European Commission has already approved the extension of the Imvanex vaccine, from the Danish company Bavarian Nordic, once morest monkeypox. This product has been approved in the EU since 2013 for the prevention of smallpox. ATS